AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
Tadashi MatsushitaNobuaki SuzukiAzusa NagaoChiai NagaeHaruko Yamaguchi-SuitaYui KyogokuAkiko IokaKeiji NogamiPublished in: BMJ open (2022)
jRCTs041200037.